Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy
NCT07021430Phase 1Recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dihydroartemisinin + piperaquine in malaria (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Percent of eligible household members receiving fMDA at 5 months. Started Apr 2026; status: recruiting.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07021430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021430.